Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Fulcrum Therapeutics (FULC)
NASDAQ:FULC
Holding FULC?
Track your performance easily
FULC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.86 - $13.70
Previous Close$3.01
Volume462.14K
Average Volume (3M)1.67M
Market Cap
$161.55M
Enterprise Value-$85.73M
Total Cash (Recent Filing)$257.23M
Total Debt (Recent Filing)$9.14M
Price to Earnings (P/E)―
Beta1.81
Next Earnings
Feb 27, 2025EPS Estimate
-$0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.31
Shares Outstanding53,938,661
10 Day Avg. Volume1,065,810
30 Day Avg. Volume1,667,799
Standard Deviation0.52
R-Squared0.05
Alpha0.05
Financial Highlights & Ratios
Price to Book (P/B)0.63
Price to Sales (P/S)2.00
Price to Cash Flow (P/CF)-2.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-1.06
Enterprise Value/Gross Profit-30.56
Enterprise Value/Ebitda6.44
Forecast
1Y Price Target
$5.17Price Target Upside72.62% Upside
Rating ConsensusHold
Number of Analyst Covering7
Fulcrum Therapeutics News
PremiumCompany Announcements
Fulcrum Therapeutics Reports Q3 2024 Financial Progress
PremiumPre-Earnings
Is FULC a Buy, Before Earnings?
Bulls Say, Bears Say
Bulls Say
Clinical Trials And Market OpportunityRenewed interest in pociredir’s potential in sickle cell disease (SCD) has emerged following Pfizer’s recent withdrawal of Oxbryta from the market, which has reinvigorated investor discussions about pociredir’s opportunity in this space.
Financial PositionFulcrum ended the quarter with $273.8M in cash, cash equivalents, and marketable securities.
Market Dynamics In Muscular DystrophyFSHD is the second most common form of muscular dystrophy in adults and has no approved therapy, so the opportunity could be substantial.
Bears Say
Program FailureFULC announced that their lead program losmapimod did not meet its primary or secondary endpoints in its FSHD pivotal trial and the program has been discontinued.
Stock PerformanceFulcrum's stock is expected to continue to trade closer to cash until further clarity on the pipeline is garnered.
Study OutcomeThe Phase 3 REACH study of losmapimod failed to show an improvement across its primary endpoint of reachable workspace (RWS).
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
FULC FAQ
What was Fulcrum Therapeutics’s price range in the past 12 months?
Fulcrum Therapeutics lowest stock price was $2.86 and its highest was $13.70 in the past 12 months.
What is Fulcrum Therapeutics’s market cap?
Currently, no data Available
When is Fulcrum Therapeutics’s upcoming earnings report date?
Fulcrum Therapeutics’s upcoming earnings report date is Feb 27, 2025 which is in 99 days.
How were Fulcrum Therapeutics’s earnings last quarter?
Fulcrum Therapeutics released its earnings results on Nov 13, 2024. The company reported -$0.35 earnings per share for the quarter, beating the consensus estimate of -$0.396 by $0.046.
Is Fulcrum Therapeutics overvalued?
According to Wall Street analysts Fulcrum Therapeutics’s price is currently Undervalued.
Does Fulcrum Therapeutics pay dividends?
Fulcrum Therapeutics does not currently pay dividends.
What is Fulcrum Therapeutics’s EPS estimate?
Fulcrum Therapeutics’s EPS estimate is -$0.28.
How many shares outstanding does Fulcrum Therapeutics have?
Fulcrum Therapeutics has 53,938,660 shares outstanding.
What happened to Fulcrum Therapeutics’s price movement after its last earnings report?
Fulcrum Therapeutics reported an EPS of -$0.35 in its last earnings report, beating expectations of -$0.396. Following the earnings report the stock price went down -2.198%.
Which hedge fund is a major shareholder of Fulcrum Therapeutics?
Among the largest hedge funds holding Fulcrum Therapeutics’s share is RA Capital Management. It holds Fulcrum Therapeutics’s shares valued at 41M.
---
Fulcrum Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$5.17 (72.62% Upside)
$5.17 (72.62% Upside)
Blogger Sentiment
Bullish
FULC Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.6%
Last 30 Days ▲ 1.2%
Last 30 Days ▲ 1.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.46%
12-Months-Change
Fundamentals
Return on Equity
-6.99%
Trailing 12-Months
Asset Growth
0.05%
Trailing 12-Months
Company Description
Fulcrum Therapeutics
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.
---
FULC Earnings Call
Q3 2024
0:00 / 0:00
---
FULC Stock 12 Month Forecast
Average Price Target
$5.17
▲(72.62% Upside)
Technical Analysis
Arcutis Biotherapeutics
―
Rocket Pharmaceuticals
―
Immunovant
―
Voyager Therapeutics
―
Best Analysts Covering FULC
1 Year
1 Year Success Rate
5/11 ratings generated profit
1 Year Average Return
+20.46%
reiterated a buy rating 7 days ago
Copying Matthew Biegler's trades and holding each position for 1 Year would result in 45.45% of your transactions generating a profit, with an average return of +20.46% per trade.
---